Can I Take Alpha-Lipoic Acid with Cialis (Tadalafil)?

Tadalafil is a prescription phosphodiesterase type 5 (PDE5) inhibitor sold under the brand name Cialis for erectile dysfunction and benign prostatic hyperplasia, and under the brand name Adcirca at a higher dose for pulmonary arterial hypertension. Alpha-lipoic acid (ALA, also called thioctic acid) is an over-the-counter antioxidant supplement, not an FDA-approved drug in the United States, commonly taken at 300 to 600 mg per day for glycemic support or nerve-related symptoms.

There is no known pharmacokinetic interaction between alpha-lipoic acid and tadalafil: the two do not compete for the same liver enzyme in any way documented in the tadalafil label. The relevant concern is pharmacodynamic overlap. ALA can lower blood glucose, and tadalafil produces mild vasodilation and a small blood-pressure reduction; taken together, particularly at higher tadalafil doses or in a person prone to low blood sugar, the combined effect could produce dizziness or lightheadedness. No controlled trial has specifically tested this drug-supplement pair for safety, so this assessment rests on the pharmacology of each agent individually rather than on direct interaction data.

What each substance does

Tadalafil inhibits PDE5, the enzyme that breaks down cyclic GMP in smooth muscle. Prolonging cGMP signaling relaxes smooth muscle in the penis (enabling erection), the bladder neck and prostate (improving BPH symptoms), and the pulmonary vasculature (the basis for the Adcirca indication). This relaxation also produces a small amount of systemic vasodilation. The FDA-approved prescribing information for tadalafil describes only a modest mean blood-pressure reduction compared with placebo in healthy volunteers, and it carries specific warnings about combining tadalafil with nitrates (an absolute contraindication) and with alpha-blockers such as tamsulosin (a documented additive hypotension risk requiring dose timing precautions).

Alpha-lipoic acid is a naturally occurring compound involved in mitochondrial energy metabolism. As a supplement it is marketed for antioxidant support, insulin sensitivity, and peripheral nerve symptoms, most often in people with diabetes. It is not regulated by the FDA as a drug, so dose, purity, and co-formulation with other ingredients vary by manufacturer.

Men taking tadalafil are disproportionately likely to have metabolic risk factors, since erectile dysfunction and diabetes share overlapping vascular and neurologic causes. That overlap is why ALA and tadalafil end up in the same medicine cabinet often enough to warrant this guide.

The main interaction: overlapping blood sugar and blood pressure effects

ALA is reported in the clinical literature to modestly lower fasting blood glucose, an effect generally attributed to increased cellular glucose uptake. Tadalafil separately produces mild vasodilation, most pronounced in the hours after an on-demand dose (10 or 20 mg) rather than during steady-state daily 5 mg dosing. Neither effect is large on its own. The concern is timing overlap: if a large ALA dose is taken on an empty stomach at the same time as an on-demand tadalafil dose, a person with pre-diabetes, diabetes, or borderline low blood pressure could experience symptomatic lightheadedness from the combination, even though each agent individually would be well tolerated.

People at higher risk for this overlap include those who:

• Have diabetes or pre-diabetes and take ALA specifically for glycemic support
• Use insulin or a sulfonylurea, where added glucose lowering from ALA could tip toward hypoglycemia
• Take tadalafil on demand at 10 to 20 mg rather than the daily 5 mg regimen
• Also take an alpha-blocker (such as tamsulosin) for BPH, a combination the tadalafil label already flags for additive blood-pressure lowering
• Take either agent on an empty stomach

People with normal glucose metabolism and stable blood pressure who take low-dose daily tadalafil are at low risk from this combination. A reasonable general precaution for anyone combining the two is to take ALA with food and to notice whether lightheadedness occurs within a couple of hours of either dose.

A less certain concern: thyroid hormone conversion

Some animal research has suggested that high-dose lipoic acid may interfere with the enzymes that convert thyroxine (T4) into the active hormone triiodothyronine (T3). Human data on this effect at typical supplemental doses are limited, and this concern should be treated as plausible rather than established. It matters here only indirectly: thyroid dysfunction is itself a recognized contributor to sexual dysfunction, so a person taking tadalafil for erectile dysfunction who also has undiagnosed or under-treated hypothyyroidism could see less benefit from tadalafil if an unrelated factor (thyroid hormone status) is not addressed. Tadalafil itself has no known direct effect on thyroid function.

Anyone taking high-dose ALA (above the commonly used 600 mg/day range) alongside thyroid replacement therapy should discuss periodic thyroid function testing with their prescriber. This is a monitoring suggestion based on plausible mechanism, not a documented clinical outcome specific to tadalafil users.

A related lab-testing issue: biotin

Many "metabolic support" or "nerve health" supplements combine ALA with high-dose biotin. The FDA has warned that high-dose biotin can distort common thyroid immunoassay results (falsely raising free T4 and suppressing TSH readings) without reflecting a true change in thyroid hormone levels. This is a laboratory interference issue, not a drug interaction, but anyone on a combined ALA-biotin product should tell their lab or clinician before thyroid testing, since results can otherwise be misread. (Source: FDA safety communication on biotin interference with lab tests.)

Does ALA change tadalafil blood levels?

Tadalafil is metabolized primarily by the liver enzyme CYP3A4, according to its FDA label. Strong CYP3A4 inhibitors (such as ketoconazole or ritonavir) raise tadalafil blood levels, and strong inducers (such as rifampin) lower them substantially, which is why the label carries dosing cautions around those drug classes. Alpha-lipoic acid at typical supplemental doses (300 to 600 mg/day) has not been characterized as a clinically significant CYP3A4 inhibitor or inducer in the available literature. Based on current evidence, standard-dose ALA is not expected to meaningfully change tadalafil blood levels.

At doses above roughly 1,200 mg/day, sometimes used in neuropathy treatment protocols under medical supervision, dedicated pharmacokinetic interaction data are not established. This is a gap in the evidence rather than a documented safety signal, and it is a reasonable point to raise with a pharmacist if using ALA at that range.

Practical guidance

1. Take ALA with food. This blunts its transient glucose-lowering peak and may reduce the chance of lightheadedness when combined with tadalafil.
2. Start at a lower ALA dose and increase gradually if you are new to the supplement, so you can judge your own tolerance before layering in a PDE5 inhibitor.
3. If you use on-demand tadalafil (10 to 20 mg), consider avoiding a large ALA dose on an empty stomach in the same two-hour window, particularly if you have diabetes or low baseline blood pressure.
4. If you take an alpha-blocker for BPH, follow your prescriber's timing instructions for tadalafil and alpha-blocker separation; adding ALA does not remove the need for that spacing.
5. Never combine tadalafil with nitrate medications for chest pain, regardless of supplement use; this is an absolute, unrelated contraindication on the tadalafil label.

Who should talk to a clinician or pharmacist before combining

• Anyone with diabetes managed with insulin or a sulfonylurea
• Anyone with treated or suspected hypothyroidism, especially if considering ALA doses above 600 mg/day
• Anyone taking an alpha-blocker or any blood-pressure-lowering medication alongside tadalafil
• Anyone considering ALA doses used in neuropathy protocols (above roughly 600 to 1,200 mg/day) rather than typical supplement-label doses

What the evidence does and does not show

Evidence quality and limits of this guidance

No published randomized controlled trial has directly examined the safety profile or interaction potential when alpha-lipoic acid is used alongside tadalafil. This article's evaluation draws on the distinct pharmacological profiles of each substance: tadalafil's FDA-approved prescribing information, the established glucose-regulating properties of alpha-lipoic acid, and FDA guidelines regarding biotin's potential to affect laboratory results. Quantitative claims found elsewhere regarding alpha-lipoic acid's effects on glucose levels, blood pressure readings, or measures of erectile function warrant verification against the original research; during preparation of this article, several reported values could not be confirmed by consulting the primary literature. While the lack of documented severe interactions between alpha-lipoic acid and tadalafil in published sources is encouraging, it does not conclusively exclude the possibility of interaction, as adverse events involving supplements and prescription medications tend to be underreported in medical literature.

If you experience dizziness, fainting, chest pain, or a sudden drop in blood pressure after taking tadalafil with any supplement, stop and seek urgent medical care rather than waiting for a routine follow-up.

Special populations

Diabetes. This group carries the most overlapping risk factors: possible use of glucose-lowering medications, possible autonomic or blood-pressure instability, and frequent use of ALA for neuropathy symptoms. Glucose monitoring is the most actionable step if starting or adjusting ALA dose in this group.

Daily low-dose tadalafil for BPH. The 5 mg once-daily FDA-approved regimen produces steady blood levels without sharp peaks, which likely lowers the chance of a noticeable combined blood-pressure effect compared with on-demand higher-dose use. Men on this regimen for BPH are, on average, older and more likely to have cardiovascular comorbidities, so modest blood-pressure changes still deserve attention.

Pulmonary arterial hypertension (tadalafil 40 mg daily, Adcirca). At this dose, systemic vasodilation is more pronounced than at ED or BPH doses. Adding any supplement with vascular or glucose-lowering effects in this population should go through the prescribing cardiologist or pulmonary hypertension specialist rather than being self-managed.

Frequently asked questions